Loading company details...
Beta
Latest Form 4 (Oct 2, 2026): Jonathan Allan (GENERAL COUNSEL & CORP SEC): Sale of 627 shares, $16.5K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Jonathan Allan, GENERAL COUNSEL & CORP SEC | Sale | 627 | $16.5K |
| Oct 2, 2026 | Barry Ticho, CHIEF MEDICAL OFFICER | Sale | 1,051 | $27.5K |
| Sep 25, 2026 | Alexander Cumbo | Grant/Award | 39,674 | n/a |
| Sep 3, 2026 | Barry Ticho, CHIEF MEDICAL OFFICER | Sale | 3,945 | $120.4K |
| Aug 19, 2026 | Barry Ticho, CHIEF MEDICAL OFFICER | Exercise/Conversion | 10,000 | n/a |
| Aug 19, 2026 | Edward M. Kaye Md. | Exercise/Conversion | 26,250 | n/a |
| Aug 19, 2026 | Jonathan Allan, GENERAL COUNSEL & CORP SEC | Exercise/Conversion | 6,000 | n/a |
| Aug 5, 2026 | Barry Ticho, CHIEF MEDICAL OFFICER | Sale | 5,907 | $171.0K |
| Jul 17, 2026 | Seth Loring Harrison | Gift | 29,555 | n/a |
| Jul 17, 2026 | Thomas McCauley, Chief Scientific Officer | Grant/Award | 225,000 | n/a |